161 related articles for article (PubMed ID: 1988235)
1. Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions.
Rieder MJ; Shear NH; Kanee A; Tang BK; Spielberg SP
Clin Pharmacol Ther; 1991 Jan; 49(1):13-7. PubMed ID: 1988235
[TBL] [Abstract][Full Text] [Related]
2. Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity.
Shear NH; Spielberg SP; Grant DM; Tang BK; Kalow W
Ann Intern Med; 1986 Aug; 105(2):179-84. PubMed ID: 3729200
[TBL] [Abstract][Full Text] [Related]
3. Acetylator phenotype and genotype in HIV-infected patients with and without sulfonamide hypersensitivity.
O'Neil WM; MacArthur RD; Farrough MJ; Doll MA; Fretland AJ; Hein DW; Crane LR; Svensson CK
J Clin Pharmacol; 2002 Jun; 42(6):613-9. PubMed ID: 12043950
[TBL] [Abstract][Full Text] [Related]
4. Acetylator phenotyping in patients with malignant lymphomas, using caffeine as the metabolic probe.
William BM; Abdel-tawab AM; Hassan EA; Mohamed OF
Pol J Pharmacol; 2004; 56(4):445-9. PubMed ID: 15520499
[TBL] [Abstract][Full Text] [Related]
5. Prospective evaluation of detoxification pathways as markers of cutaneous adverse reactions to sulphonamides in AIDS.
Wolkenstein P; Loriot MA; Aractingi S; Cabelguenne A; Beaune P; Chosidow O
Pharmacogenetics; 2000 Dec; 10(9):821-8. PubMed ID: 11191886
[TBL] [Abstract][Full Text] [Related]
6. N-acetyltransferases: pharmacogenetics and clinical consequences of polymorphic drug metabolism.
Spielberg SP
J Pharmacokinet Biopharm; 1996 Oct; 24(5):509-19. PubMed ID: 9131488
[TBL] [Abstract][Full Text] [Related]
7. Genetically determined variability in acetylation and oxidation. Therapeutic implications.
Clark DW
Drugs; 1985 Apr; 29(4):342-75. PubMed ID: 2859977
[TBL] [Abstract][Full Text] [Related]
8. Caffeine acetylator phenotyping during maturation in infants.
Pariente-Khayat A; Pons G; Rey E; Richard MO; D'Athis P; Moran C; Badoual J; Olive G
Pediatr Res; 1991 May; 29(5):492-5. PubMed ID: 1896253
[TBL] [Abstract][Full Text] [Related]
9. Interindividual and intraindividual variability in acetylation: characterization with caffeine.
Hardy BG; Lemieux C; Walker SE; Bartle WR
Clin Pharmacol Ther; 1988 Aug; 44(2):152-7. PubMed ID: 3396262
[TBL] [Abstract][Full Text] [Related]
10. Acetylator phenotyping: the urinary caffeine metabolite ratio in slow acetylators correlates with a marker of systemic NAT1 activity.
Cribb AE; Isbrucker R; Levatte T; Tsui B; Gillespie CT; Renton KW
Pharmacogenetics; 1994 Jun; 4(3):166-70. PubMed ID: 7920698
[TBL] [Abstract][Full Text] [Related]
11. Acetylation phenotype and cutaneous hypersensitivity to trimethoprim-sulphamethoxazole in HIV-infected patients.
Carr A; Gross AS; Hoskins JM; Penny R; Cooper DA
AIDS; 1994 Mar; 8(3):333-7. PubMed ID: 8031511
[TBL] [Abstract][Full Text] [Related]
12. Determination of acetylator phenotype in Caucasians with caffeine.
Hildebrand M; Seifert W
Eur J Clin Pharmacol; 1989; 37(5):525-6. PubMed ID: 2598993
[TBL] [Abstract][Full Text] [Related]
13. [Clinical relevance of N-acetyltransferase type 2 (NAT2) genetic polymorphism].
Furet Y; Bechtel Y; Le Guellec C; Bechtel PR; Autret-Leca E; Paintaud G
Therapie; 2002; 57(5):427-31. PubMed ID: 12611196
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis of sulfonamide hypersensitivity reactions by in-vitro "rechallenge" with hydroxylamine metabolites.
Rieder MJ; Uetrecht J; Shear NH; Cannon M; Miller M; Spielberg SP
Ann Intern Med; 1989 Feb; 110(4):286-9. PubMed ID: 2913915
[TBL] [Abstract][Full Text] [Related]
15. Determination of N-acetylator phenotype using caffeine as a probe compound: a comparison of high-performance liquid chromatography and capillary electrophoresis methods.
Lloyd DK; Fried K; Wainer IW
J Chromatogr; 1992 Jul; 578(2):283-91. PubMed ID: 1400808
[TBL] [Abstract][Full Text] [Related]
16. Relationship between high incidence of adverse dapsone reactions and slow acetylate phenotype or low plasma/lymphocyte glutathione level.
Guo R; Thormann W; Lauterberg B
Chin Med J (Engl); 1996 Dec; 109(12):933-6. PubMed ID: 9275325
[TBL] [Abstract][Full Text] [Related]
17. Acetylator phenotype in patients with p-phenylenediamine allergy.
Kawakubo Y; Nakamori M; Schöpf E; Ohkido M
Dermatology; 1997; 195(1):43-5. PubMed ID: 9267736
[TBL] [Abstract][Full Text] [Related]
18. A simplified and rapid test for acetylator phenotyping by use of the peak height ratio of two urinary caffeine metabolites.
el-Yazigi A; Chaleby K; Martin CR
Clin Chem; 1989 May; 35(5):848-51. PubMed ID: 2566399
[TBL] [Abstract][Full Text] [Related]
19. Caffeine metabolism in a healthy Spanish population: N-acetylator phenotype and oxidation pathways.
Carrillo JA; Benítez J
Clin Pharmacol Ther; 1994 Mar; 55(3):293-304. PubMed ID: 8143395
[TBL] [Abstract][Full Text] [Related]
20. Acetylation phenotypes and biological variation in a French Caucasian population.
Pontes ZB; Vincent-Viry M; Gueguen R; Galteau MM; Siest G
Eur J Clin Chem Clin Biochem; 1993 Feb; 31(2):59-68. PubMed ID: 8467011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
